Application of a New Paradigm for Cytomegalovirus Disease Prevention in Mayo Clinic's First Face Transplant

[1]  Deepali Kumar,et al.  Evaluation of a Novel Global Immunity Assay to Predict Infection in Organ Transplant Recipients , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  S. Suominen,et al.  The Helsinki Face Transplantation: Surgical aspects and 1-year outcome. , 2017, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[3]  J. Germer,et al.  Comparison of Standardized Cytomegalovirus (CMV) Viral Load Thresholds in Whole Blood and Plasma of Solid Organ and Hematopoietic Stem Cell Transplant Recipients with CMV Infection and Disease , 2017, Open forum infectious diseases.

[4]  M. Siemionow.  The decade of face transplant outcomes , 2017, Journal of Materials Science: Materials in Medicine.

[5]  F. Bellivier,et al.  Face transplant: long-term follow-up and results of a prospective open study , 2016, The Lancet.

[6]  B. Pomahac,et al.  Guillain–Barré syndrome associated with resistant cytomegalovirus infection after face transplantation , 2016, Transplant infectious disease : an official journal of the Transplantation Society.

[7]  E. Blumberg,et al.  It's not too late: a proposal to standardize the terminology of “late‐onset” cytomegalovirus infection and disease in solid organ transplant recipients , 2015, Transplant infectious disease : an official journal of the Transplantation Society.

[8]  R. Razonable,et al.  Immune-based monitoring for cytomegalovirus infection in solid organ transplantation: is it ready for clinical primetime? , 2014, Expert review of clinical immunology.

[9]  A. Caliendo,et al.  Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  M. Ison,et al.  Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  B. Pomahac,et al.  Infections Following Facial Composite Tissue Allotransplantation—Single Center Experience and Review of the Literature , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  A. Humar,et al.  Cytomegalovirus in Solid Organ Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  R. Avery,et al.  What is the true significance of donor-related cytomegalovirus transmission in the setting of facial composite tissue allotransplantation? , 2011, Transplantation proceedings.

[14]  T. Gómez-Cía,et al.  First Face Composite-Tissue Transplant Recipient Successfully Treated for Cytomegalovirus Infection with Preemptive Valganciclovir Treatment , 2011, Antimicrobial Agents and Chemotherapy.

[15]  S. Schneeberger,et al.  The World's Experience With Facial Transplantation: What Have We Learned Thus Far? , 2009, Annals of plastic surgery.

[16]  J. Fung,et al.  Near-total human face transplantation for a severely disfigured patient in the USA , 2009, The Lancet.

[17]  O. Manuel,et al.  Cell‐Mediated Immunity to Predict Cytomegalovirus Disease in High‐Risk Solid Organ Transplant Recipients , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  F. Bellivier,et al.  Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study , 2008, The Lancet.

[19]  A. Sirigu,et al.  Outcomes 18 months after the first human partial face transplantation. , 2007, The New England journal of medicine.

[20]  M. Kon,et al.  Risk Assessment of Immunosuppressive Therapy in Facial Transplantation , 2007, Plastic and reconstructive surgery.